Brigatinib

(Alunbrig®)

Brigatinib

Drug updated on 11/13/2023

Dosage FormTablet (oral: 30 mg, 90 mg, 180 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Product Monograph / Prescribing Information

Document TitleYearSource
Alunbrig (Brigatinib) Prescribing Information.2022Takeda Pharmaceutical Company Limited, Cambridge, MA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
A systematic review of the cost-effectiveness analyses of anaplastic lymphoma kinase (ALK) inhibitors in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).2023PharmacoEconomics
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.2022Cochrane Database of Systematic Reviews
Comparative efficacy of ALK inhibitors for treatment-naïve ALK-positive advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis.2022International Journal of Molecular Sciences
Clinical guidance report: brigatinib (Alunbrig) for anaplastic lymphoma kinase positive non-small cell lung cancer. 2021CADTH
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor–naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.2021Journal of Chemotherapy
Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer.2021Cancers
Comparative efficacy and safety of lorlatinib and alectinib for alk-rearrangement positive advanced non-small cell lung cancer in asian and non-asian patients: a systematic review and network meta-analysis.2021Cancers
Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: a systematic review and network meta-analysis.2020Cancers
Clinical guidance report: brigatinib (Alunbrig) for non-small cell lung cancer (NSCLC).2019CADTH
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.2018Oncotarget

Clinical Practice Guidelines